Unwanted Astigmatism and High-order Aberrations One Year after Excimer and Femtosecond Corneal Surgery.

SIGNIFICANCE: Small incision lenticule extraction (SMILE) is advanced as the most minimally invasive and least traumatic corneal procedure for correcting refractive errors using a single laser. Although SMILE obtains similar results to femtosecond laser in situ keratomileusis (LASIK) with spherical myopia, it has deficiencies in astigmatism correction. PURPOSE: The purpose of this study was to compare refractive outcomes and high-order aberrations (HOAs) between SMILE and femtosecond LASIK corneal procedures at 1 year post-operative. METHODS: Ninety-two patients (181 eyes) with myopia/myopic astigmatism underwent either SMILE (group 1) or femtosecond LASIK (group 2). The refractive target was to achieve emmetropia in all cases. Data were analyzed to determine significance of change in refraction and HOAs. Furthermore, astigmatism was subjected to vector analysis using the Thibos (calculation of change, Δ, in J0 and J45 values) and Alpins (calculation of difference, ΔC, between target-induced astigmatism [TIA] and surgically induced astigmatism) methods. RESULTS: Forty-five patients (89 eyes) from group 1 and 47 patients (92 eyes) from group 2 completed the study. The main significant (P ≤ .001) findings were as follows: (a) residual astigmatism was greater in group 1; (b) group 1, ΔJ0 = 1.015J0 + 0.040 (R = 0.861), ΔJ45 = 1.082J45 + 0.019 (R = 0.792), ΔC = 0.401TIA + 0.323 (R = 0.489), and mean spherical aberration increased from -0.003 (SD, ±0.059; 95% confidence interval [CI], -0.015 to 0.009) to 0.028 µm (SD, ±0.041; 95% CI, -0.037 to -0.020); and (c) group 2, ΔJ0 = 0.952J0 - 0.005 (R = 0.921), ΔJ45 = 0.962J45 - 0.002 (R = 0.923), ΔC = 0.187TIA + 0.101 (R = 0.272), mean coma reduced from 0.114 (SD, ±0.087; 95% CI, 0.096 to 0.132) to 0.077 µm (SD, ±0.059; 95% CI, 0.065 to 0.089), and trefoil from 0.089 (SD, ±0.049; 95% CI, 0.079 to 0.0990) to 0.056 µm (SD, ±0.047; 95% CI, 0.046 to 0.066). CONCLUSIONS: In comparison with SMILE, femtosecond LASIK offered better precision in the overall control of astigmatism and HOAs.

Autologous Neurosensory Retinal Free Flap Treatment for a Large Macular Hole.

A patient presented with a large chronic macular hole (MH) of 700 µm. Best-corrected visual acuity (BCVA) was 20/200. Since the MHs edges were attached and stiff, an autologous neurosensory retinal flap was harvested and placed into the MH to close it. Perfluoro-n-octane heavy liquid (PFC) was instilled over the flap and exchanged with silicone oil (1,000 cs). Seven days postoperatively, the MH was closed, with a BCVA of 20/80 that improved to 20/60 at months 1 and 3. Optical coherence tomography and angiography showed patch incorporation with fovea formation and normal circulation. [Ophthalmic Surg Lasers Imaging Retina. 2018;49:e89-e92.].

Refractive Outcomes of Posterior Chamber Phakic Intraocular Lens Implantation for Correction of Myopia and Myopic Astigmatism.

OBJECTIVES: The aim was to examine efficacy and safety after Implantable Collamer Lens (ICL) implantation for correction of myopia et myopic astigmatism. METHODS: This prospective clinical study included 28 eyes of 16 patients which underwent implantation of ICL for correction of myopia up to -18,00 diopters (D) and myopic astigmatism up to -6,00 D in the Eye Clinic Svjetlost Sarajevo, from January 2013 to January 2016. Uncorrected distance visual acuity (UDVA), spherical equivalent (SE), corrected distance visual acuity (CDVA), intraocular pressure (IOP), endothelial cell (EC) density were evaluated at one, six and twelve months. For statistical analysis SPSS for Windows and Microsoft Excel were used. RESULTS: Out of 16 patients, with mean age of 28,21 ± 4,06 years, 12 of them had binocular and 4 of them had monocular procedure. After 12 months mean UDVA was 0,76 ± 0,16 compared to UDVA 0,04 ± 0,03 preoperatively. Mean SE preoperatively was -0,21 ± 0,27 D compared to -9,52 ± 3,69 D preoperatively. At 12 months one eye (3,57%) lost 2 Snellen lines. In this study 8 eyes (28,57%) gained 1 line, 5 eyes gained (17,56%) 2 lines, and 3 eyes (10,72%) gained 3 lines. EC loss was 5,50±4.71% after 12 months. There was no significant change of IOP by the end of 12 months follow up period. One haptic crack was reported as the only intraoperative complication. Three postoperative complications were: two lens rotations and one retinal detachment. CONCLUSION: Implantation of ICL is an effective and safe method for reducing or correcting myopia and myopic astigmatism.

The effect of intravitreal administration of bevacizumab on macular edema and visual acuity in age-related macular degeneration with subfoveolar choroidal neovascularisation.

BACKGROUND/AIM: Age-related macular degeneration (AMD) is a leading cause of the loss of central visual acuity in population older than 70 years. We can distinguish wet and dry form of AMD. The aim of the study was to present our early results in treatment of the wet (neovascular) form of AMD with intravitreal administration of bevacizumab. METHODS: The study included 39 patients. Each patient underwent a complete ophthalmological examination, fluorescein angiography (FA) and optical coherence tomography (OCT). All the patients received 1.25 mg of intravitreal bevacizumab (0.05 mL of commercial phial of Avastin). The total of three doses was given with a one-month interval between doses. RESULTS: Among 39 patients, 24 were women and 15 men. The average best corrected visual acuity (BCVA) was improved from 0.09 before the therapy to 0.24 after the administration of all the three doses of bevacizumab (p < 0.001). The average central macular thickness (CMT) measured by OCT was improved from 474 microm in the beginning to 341 microm after the administration of all the three doses of the drug (p < 0.001). There were no side effects. CONCLUSIONS: Our short-term experience indicates that intravitreal administration of three doses of bevacizumab in one-month intervals between the doses leads to a significant reduction of macular edema and improvement of BCVA in patients with neovascular AMD.

[Laser in situ keratomyleusis (LASIK) for correction of myopia and hypermetropia--our one year experience].

BACKGROUND/AIM: Laser in situ keratamileusis (LASIK) is the most commonly used refractive surgical method worldwide. The aim of this study was to examine the effectiveness and safety of LASIK in the correction of myopia and hyperopia. METHODS: The study included myopic and hyperopic eyes with preoperative best corrected visual acuity (BCVA) = 1 (20/20), of the total number of 322 divided into 2 groups--1) myopic eyes (n = 241) which were divided into 4 subgroups according to the myopia strength: a) < or = -1.75 D (n = 23), b) from -2 to -3.75 D (n = 81), c) from -4 to -6.75 D (n = 113), d) > or = -7 D (n = 24); 2) hyperopic eyes (n = 81) which were divided into 3 subgroups according to the hyperopia strength: a) < or = +1.75D (n = 10), b) from +2 to +3.75 D (n = 46), c) > or = +4 D (n = 25). Myopic and hyperopic eyes with preoperative BCVA < or = 0.9 (eyes with ambliopia) were excluded from the study, as well as eyes with astigmatism > 1.5 D. To assess the effectiveness of LASIK we examined the percentage of eyes in the mentioned subgroups, which derived uncorrected visual acuity (UCVA) 6 month after the intervention to the following: a) UCVA = 1 (20/20) and b) UCVA > or = 0.5 (20/40). To assess the safety of LASIK we examined the frequency of intraoperative and postoperative complications. A prospective study was performed in a 6-months follow-up period. RESULTS. Refractive spherical equivalent (RSE) of myopic eyes was in the range from -0.75 D to -12 D. In the first subgroup preoperative mean value of RSE with standard deviation (mean RSE +/- SD) was -1.39 +/- 0.36 D, and 6 months after the LASIK 100% of the eyes had UCVA = 20/20. In the second subgroup preoperative mean RSE +/- SD was -2.85 +/- 0.50 D, and 6 months after LASIK 93% of the eyes had UCVA = 20/20, but 100% of the eyes had UCVA > or = 20/40. In the third subgroup preoperative mean RSE +/- SD was -5.03 +/- 0.75 D, and 6 months after the LASIK 90% of the eyes had UCVA = 20/20, but 100% of the eyes had UCVA > or = 20/40. In the fourth subgroup preoperative mean RSE +/- SD was -7.68 +/- 1.03 D, and 6 months after the LASIK 96% of the eyes had UCVA = 20/20, but 100% of eyes had UCVA > or = 20/40. Refractive spherical equivalent of hyperopic eyes was in the range from +1 D to +6 D. In the first subgroup preoperative mean RSE +/- SD was +1.50 +/- 0.30 D, and 6 months after the LASIK 90% of the eyes had UCVA = 20/20, but 100% of the eyes had UCVA > or = 20/40. In the second subgroup preoperative mean RSE +/- SD was +2.65 +/- 0.46 D, and 6 months after the LASIK 87% of the eyes had UCVA = 20/20, but 96% of the eyes had UCVA > or = 20/40. In the third subgroup preoperative mean RSE +/- SD was +4.62 +/- 0.68 D, and 6 months after the LASIK 64% of the eyes had UCVA = 20/20, but 100% of the eyes had UCVA > or = 20/40. In our study intraoperative complications appeared in 6 eyes (1.86%): thin flap in 2 eyes (0.62%) and epithelial defects in 4 eyes (1.24%), yet postoperative complications appeared in 10 eyes (3.10%): flap folds in 2 eyes (0.62%), epithelial ingrowth in 4 eyes (1.24%) and regression in 4 eyes (1.24%). CONCLUSION: LASIK is effective and safe refractive surgical method for correcting myopia up to -12 D and hyperopia up to +6 D.